Alembic Pharma gets USFDA EIR for API Facility at Karakhadi

Gujrat: Alembic Pharmaceuticals Limited has announced that it has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at its API Facility at Karakhadi during the period from 13th January 2020 to 17th January 2020.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.

Read also: Alembic Pharma bags USFDA nod for doxycycline hyclate tablets

Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Read also: Alembic Pharma Gets 4 Observations From USFDA For Panelav Facility